COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, J.Y. | - |
dc.contributor.author | Seo, Y.B. | - |
dc.contributor.author | Kim, E.J. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kim, Y.R. | - |
dc.contributor.author | Yoon, J.G. | - |
dc.contributor.author | Noh, J.Y. | - |
dc.contributor.author | Cheong, H.J. | - |
dc.contributor.author | Kim, W.J. | - |
dc.contributor.author | Yoon, S.-Y. | - |
dc.contributor.author | Choi, J.-Y. | - |
dc.contributor.author | Lee, Y.J. | - |
dc.contributor.author | Lee, H.W. | - |
dc.contributor.author | Kim, S.S. | - |
dc.contributor.author | Kim, B. | - |
dc.contributor.author | Song, J.Y. | - |
dc.date.accessioned | 2022-11-19T23:40:31Z | - |
dc.date.available | 2022-11-19T23:40:31Z | - |
dc.date.created | 2022-11-18 | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/146031 | - |
dc.description.abstract | Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood samples before and after sequential two-dose vaccinations of BNT162b2 and ChAdOx1 nCoV-19. Outcomes included anti-S IgG antibody and neutralizing antibody responses, adverse events, and proinflammatory cytokine responses. A total of 59 and 57 participants vaccinated with BNT162b2 and ChAdOx1 nCoV-19, respectively, were enrolled. Systemic adverse events were more common after the first ChAdOx1 nCoV-19 dose than after the second. An opposite trend was observed in BNT162b2 recipients. Although the first ChAdOx1 nCoV-19 dose significantly elevated the median proinflammatory cytokine levels, the second dose did not, and neither did either dose of BNT162b2. Grades of systemic adverse events in ChAdOx1 nCoV-19 recipients were significantly associated with IL-6 and IL-1β levels. Anti-S IgG and neutralizing antibody titers resulting from the second BNT162b2 dose were significantly associated with fever. In conclusion, systemic adverse events resulting from the first ChAdOx1 nCoV-19 dose may be associated with proinflammatory cytokine responses rather than humoral immune responses. Febrile reactions after second BNT162b2 dose were positively correlated with vaccine-induced immune responses rather than with inflammatory responses. Copyright © 2022 Heo, Seo, Kim, Lee, Kim, Yoon, Noh, Cheong, Kim, Yoon, Choi, Lee, Lee, Kim, Kim and Song. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Noh, J.Y. | - |
dc.contributor.affiliatedAuthor | Song, J.Y. | - |
dc.identifier.doi | 10.3389/fimmu.2022.975363 | - |
dc.identifier.scopusid | 2-s2.0-85138151255 | - |
dc.identifier.bibliographicCitation | Frontiers in Immunology, v.13 | - |
dc.relation.isPartOf | Frontiers in Immunology | - |
dc.citation.title | Frontiers in Immunology | - |
dc.citation.volume | 13 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | cytokine | - |
dc.subject.keywordAuthor | immunogenicity | - |
dc.subject.keywordAuthor | reactogenicity | - |
dc.subject.keywordAuthor | vaccine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.